^
    Back
    Association details:
    Biomarker:NRAS Q61K
    Cancer:Melanoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

    Excerpt:
    The presence of a secondary mutation in NRASQ61K, in addition to the BRAFV600E mutation, in the in vitro acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376, was associated with resistance to vemurafenib but sensitivity to AZD6244...
    DOI:
    10.1371/journal.pone.0028973